Banca de QUALIFICAÇÃO: JONATAS OLIVEIRA DA SILVA

Uma banca de QUALIFICAÇÃO de DOUTORADO foi cadastrada pelo programa.
STUDENT : JONATAS OLIVEIRA DA SILVA
DATE: 22/08/2022
TIME: 14:00
LOCAL: Link: meet.google.com/woh-deqj-qdz
TITLE:

DEVELOPMENT OF PROTEINS FOR KITS OF RUBELLA DIAGNOSIS AIMING TO TRANSFER TECHNOLOGY

KEY WORDS:

Rubella virus; German measles; Rubella diagnosis

PAGES: 49
BIG AREA: Ciências Biológicas
AREA: Bioquímica
SUBÁREA: Biologia Molecular
SUMMARY:

Rubella is a disease of epidemiological importance caused by infection with the rubella virus (RV). The virus is transmitted by infected people through airborne droplets. Many cases of congenital anomalies or fetal deaths have been reported following RV infections during the first 16 weeks of pregnancy. These congenital anomalies are particular to congenital rubella syndrome (CRS), including deafness, eye disorders, and heart disease, in addition to other late sequelae, including autism, diabetes mellitus, and thyroid dysfunction. One of the biggest challenges in the control of Rubella is the development of diagnostic strategies that allow its identification with high accuracy, and, at the same time, can be applied in poor or developing countries. Therefore, an Escherichia coli BL21 (DE3) pLysS strain harboring the MERUB::pET21a vector was then used to express rMERUB recombinant protein and the yield was studied by Response Surface Methodology. IPTG inducer concentration, cell density before induction, post-induction period, and post-induction temperature were evaluated. The FFD demonstrated that all factor's effects on the linear model and 2-way interactions (IPTG*period; IPTG*cell density; IPTG*temperature) are significant (α = 0.05) in the variation of the rMERUB yield response, however, an adjustment in the modeling of the optimal region for the rMERUB yield by CCRD is necessary. The serological ELISA using rMERUB recombinant protein purified as a coating antigen (62.5 ng/well) and an anti-human IgG HRP-conjugated (1:4,000 v/v) for the detection of antibodies to RV in human sera (1:40 v/v at 30 minutes) demonstrates the recombinant protein was able to be significantly recognized by antibodies present in the serum of all samples tested. Finally, the company BIOCLIN – QUIBASA showed interest in using the antigens from this work to build commercial rubella diagnostic kits.

BANKING MEMBERS:
Presidente - 1367304 - ALEXSANDRO SOBREIRA GALDINO
Interna - 2045083 - TELMA PORCINA VILAS BOAS DIAS
Externa ao Programa - 1581667 - DANYELLE ROMANA ALVES RIOS